A Phase 1, Two Parts, Open-label, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) in Healthy Volunteers and Evaluation of Potential Drug-Drug Interactions
Latest Information Update: 10 Dec 2025
At a glance
- Drugs EYP 651 (Primary) ; Vonafexor (Primary)
- Indications Diabetic nephropathies; Hepatitis B; Hereditary nephritis; Kidney disorders; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors ENYO Pharma
Most Recent Events
- 13 Oct 2025 Status changed from planning to not yet recruiting.
- 19 Jun 2025 New trial record
- 12 Jun 2025 According to ENYO Pharma media release, company has finalized its Series C financing round with a 6 million euro investment from Vesalius Biocapital IV, bringing the total Series C raise to 32 million euro which will extend ENYO's cash runway through the second half of 2026 and enables the initiation of this study.